Deciphering trial data can be a fascinating pastime, especially when the findings indicate a medication is truly capable of making a difference for patients. Other times, however, this activity can cause consternation if the results suggest something may be awry. Such may be the case with Phase III data released the other day by Insmed for its Arikace antibiotic for cystic fibrosis sufferers.
Help employers find you! Check out all the jobs and post your resume.
